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Abstract
Targeted nanoparticles are being pursued for a range of medical applications. Here, we utilized 
targeted nanoparticles (synthetic platelets) to halt bleeding in acute trauma. One of the major 
questions that arises in the field is the role of surface ligand density on targeted nanoparticles’ 
performance. We developed intravenous hemostatic nanoparticles (GRGDS-NP1), and previously 
demonstrated their ability to reduce bleeding following femoral artery injury and increase survival 
after lethal liver trauma in the rat. These nanoparticles are made from block copolymers, 
poly(lactic-co-glycolic acid)-b- poly-ι-lysine-b-poly(ethylene glycol). Surface-conjugated 
targeting ligand density can be tightly controlled with this system, and here we investigated the 
effect of varying density on hemostasis and biodistribution. We increased the targeting peptide 
(GRGDS) concentration 100-fold (GRGDS-NP100) and undertook an in vitro dose-response study 
using rotational thromboelastometry (ROTEM), finding GRGDS-NP100 hemostatic nanoparticles 
were efficacious at doses at least 10-fold lower than the GRGDS-NP1. These results were 
recapitulated in vivo, demonstrating efficacy at 8-fold lower concentration after lethal liver 
trauma. 1-hour survival increased to 92%, compared to a scrambled peptide control, 45% 
(OR=14.4, 95% CI=[1.36, 143]), a saline control, 47% (OR=13.5, 95% CI=[1.42, 125]), and 
GRGDS-NP1, 80% (OR=1.30, n.s.). This work demonstrates the impact of changing synthetic 
platelet ligand density on hemostasis, and lays the foundation for methods to determine optimal 
ligand concentration parameters.
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Targeted nanotherapeutics have been developed for a broad range of medical 
applications.1–3 Factors that influence targeting efficacy include ligand-receptor affinities4, 
heteromultivalent ligand targeting strategies5, ligand presentation (linkers)6–8, as well as 
targeting ligand density. Studies to determine optimal surface ligand densities have 
demonstrated unique challenges specific to each material, ligand and application 
combination.9–15 We have previously developed intravenously injectable nanoparticles that 
augment hemostasis after injury.16, 17 In order to further optimize these nanoparticles for 
platelet targeting, reliable methods are needed that allow for tuning and measuring the effect 
of targeting-ligand densities.
These hemostatic nanoparticles are made of biodegradable block copolymers, reducing the 
risk of long-term inflammatory reactions. They consist of a nanoparticle core of 
biodegradable block copolymer of poly(lactic-co-glycolic acid) (PLGA) and poly-ι-lysine 
(PLL) with poly(ethylene glycol) (PEG) arms terminated with arginine-glycine-aspardic 
acid (GRGDS)-based targeting ligands. GRADSP ligands are used as a scrambled peptide to 
control for nonspecific actions of the particles (Scrambled-NPs). For research purposes, the 
nanoparticles have been loaded with coumarin-6, a fluorescent dye that allows us to track 
their biodistribution as previously described.16, 17
We previously investigated the role of targeting peptide length and PEG arm length on the 
efficacy of these hemostatic nanoparticles (NP’s), but the impact of ligand density on this 
system has not yet been addressed.17 From the literature, ligand density is known to play a 
critical role in targeting of nanoparticles. 9–13 Gu et al. developed a method to precisely 
engineer targeting-ligand-tunable nanoparticles for prostate cancer drug delivery and 
identified the narrow conjugation ratio that optimized targeting (5% for this application).9 
Fakhari et al. varied the ligand density of Cyclo-(1,12)-PenITDGEATDSGC (cLABL) on 
PLGA nanoparticles to optimize the targeting of intercellular adhesion molecule-1 
(ICAM-1), and found that the optimal density was roughly (50:50), and that particles with 
higher conjugation density performed worse.13 In all cases, the “optimal” conjugation of 
targeting ligand was highly application and condition-specific. In terms of the RGD-GPIIb/
IIIa interaction that our nanoparticles utilize to augment platelet-platelet aggregation, there 
is evidence suggesting that receptor density may play a large role in determining the nature 
and strength of this interaction. 15 Coller et al. found that platelet binding to high density 
fibrinogen prevents aggregation of platelets to a plate through “paradoxical loss of luminal 
receptors”.15
Several groups, including our own, have investigated the concept of hemostatic particles to 
mitigate complications with sourcing, storage, immunocompatibility, and administration in 
the field of blood-product transfusions. These particles have shown vast promise along with 
an array of challenges.16–24 These challenges include establishing a small homogenous 
particle size20, avoiding promotion of nonspecific aggregation25, making design choices 
about targeting ligands, and hetero-multi-functionality5, 26, optimizing targeting-linker 
length17, 19, and demonstrating efficacy in both in vivo16, 17, 27 and relevant in vitro 
models.21, 28
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Trauma is the leading cause of death for individuals between ages 1–44, and uncontrolled 
hemorrhage accounts for nearly one third of trauma-associated mortality.29 In combat, 
injuries can be especially severe and can be exacerbated by a prolonged pre-hospital phase, 
defined as the time between injury and admission to the hospital.30, 31 Recently, due to the 
advancement of body armor and changing warfare paradigms, the military has observed 
increased numbers of extremity injuries and internal (noncompressible) injuries (e.g. 
junctional, blast, central nervous system).30, 32, 33
We have previously shown that intravenously administered hemostatic nanoparticles 
(GRGDS-NP1) reduce bleeding times after femoral artery injury and increase survival after 
lethal liver trauma in the rat.16, 17 Here, our challenge was to develop a method for 
reproducibly controlling nanoparticle surface ligand conjugation and determine the impact 
of this change on hemostasis. We tested this change in both an in vitro assay, rotational 
thromboelastometry (ROTEM), and an in vivo model of lethal liver trauma. A dose-response 
study was undertaken utilizing ROTEM, and then applied in a lethal liver trauma in the rat. 
This work demonstrates the impact of changing synthetic platelet ligand density on 
hemostasis, and lays the foundation for methods to determine optimal ligand concentration 
parameters, providing a critical step toward translation of this nanotechnology.
METHODS
Nanoparticle Synthesis
PLGA (Resomer 503H) was purchased from Evonik Industries. Poly-ι-lysine (500–4000 Da 
MW) and PEG (~4600 Da MW) were purchased from Sigma Aldrich. All reagents were 
ACS grade and were purchased from Fisher Scientific. PLGA-PLL-PEG coblock polymer 
was made using standard bioconjugation techniques as previously described.16, 17, 38, 39
PLGA-PLL-PEG (1 g) was dissolved in anhydrous DMSO to a concentration of 100 mg/ml. 
Oligopeptides (25 mg GRGDS or GRADSP) was dissolved in 1 ml DMSO and added to the 
stirring polymer solution. This was reacted for 3 hours, and then transferred to dialysis 
tubing (SpectraPor 2 kDa MWCO). Dialysis water was changed every half hour for 4 hours 
with Type I D.I. water. The product was then snap-frozen in liquid nitrogen and lyophilized 
for 2–5 days.
The resulting quadblock copolymer PLGA-PLL-PEG-GRGDS was then dissolved to a 
concentration of 20 mg/ml in acetonitrile (120 mg/6 ml). This solution was added dropwise 
to a stirring volume of PBS. Precipitated nanoparticles form as the water-miscible solvent 
dissipates. Particles were collected using a coacervate precipitation method. Briefly, one 
mass equivalent of dry poly(acrylic acid) was added to the stirring particle suspension. 15ml 
of 1% w/v pAA was then added slowly to the stirring suspension until flocculation occurs. 
After 5 minutes, the flocculated particles were collected by centrifugation at 500g, and 
rinsed 3 times with 1% pAA (centrifuging @ 500 g, 2m, 4C between rinses). On the final 
rinse, particles were resuspended with D.I. water, snap-frozen and lyophilized for 2–5 days. 
Particles were resuspended in PBS and briefly sonicated at 4W to a total energy of 50 J 
using a probe sonicator (VCX-130, Sonics & Materials, Inc.) prior to use.
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As previously demonstrated, successful conjugation of PLL, PEG and peptide ligands was 
confirmed using UV-spectroscopy, 1H-NMR and amino acid analysis HPLC (BioRad, 
Varian and Shimadzu respectively).16 Nanoparticles from 5 independent syntheses batches 
were characterized for size distribution using dynamic light scattering (90Plus, Brookhaven 
Instruments Corporation) and zeta potential (Zeta Pals, Brookhaven Instruments 
Corporation). Reported figures from DLS are given as number average. Scanning electron 
microscopy was performed to visualize particle morphology (Hitachi S4500).
Amino acid analysis (AAA) was used to quantify the GRGDS peptide conjugation to the 
triblock polymer PLGA-PLL-PEG. The outcome arg:lys ratio was used to measure this 
relative conjugation efficiency. Briefly, a 5 mg aliquot of polymer was hydrolyzed for 24 h 
in a hydrolysis/derivitization workstation (Eldex Laboratories, Inc., Napa, CA). The 
hyrolysate was then neutralized with a redrying solution (ethanol: water: triethylamine in a 
2:2:1 ratio) and derivitized with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate, using 
the Water’s AccQ-Tag system. These samples were run on an HPLC (Shimadzu, with 
Water’s PicoTag Column) and measured using a fluorescence detector. Standard addition of 
known quantities of arg and lys to hydrolyzed samples was used to correct for polymer 
hydrolysate background.
Liver Trauma Model
All animal studies were performed in accordance with the Case Western Reserve University 
Institutional Animal Care and Use Committee (IACUC). Sprague Dawley rats (225–275g, 
Charles River) were anesthetized with intraperitoneal ketamine/xylazine (90:10 mg/kg, 
respectively), and injured according to the previously established liver injury model.16, 40–43 
In brief, after confirmation of complete anesthesia, the abdomen was accessed and the 
medial lobe of the liver was marked with an arch radius 1.3 cm from the suprahepatic vena 
cava using a handheld cautery device. Once marked, the tail vein was catheterized with a 
saline-flushed 24G × 3/4″ Excel Safelet Catheter. The medial liver lobe was then resected 
along the marked lines to create the injury. Treatments were administered via tail vein 
catheter immediately after injury and included saline, scrambled particles, and 
functionalized particles. All particle treatments were resuspended in a 0.5 ml PBS carrier 
solution.
The rats were allowed to bleed for 1 hour or until death, as confirmed by lack of both 
breathing and a palpable heartbeat. Before measuring blood loss, all rats were injected with 
a 1 ml lethal dose of sodium pentobarbital. The abdomen was then reopened and blood 
collected with pre-weighed gauze. The clot adherent to the liver was collected last as this 
usually caused additionally bleeding to occur. The resected liver was weighed and fixed in 
10% buffered formalin solution. Remaining liver, kidney, spleen and lungs were harvested 
and similarly preserved in 10% buffered formalin.
Biodistribution
Liver, kidney, spleen, lung and adherent clots were harvested and lyophilized for the 
biodistribution assay. The dry weight of the whole organ was recorded and 100–200 mg of 
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dry tissue was homogenized (Precellys 24) and incubated overnight in acetonitrile at 37 C. 
This dissolved any nanoparticles present in the tissue and left the C6 in the organic solvent 
solution. Tubes were then centrifuged at 15,000 g for 10 minutes to remove solid matter and 
supernatant was tested on the HPLC. Mobile phase was 80% acetonitrile, and 20% aqueous 
(8% acetic acid). Stationary phase was a Waters Symmetry C18 Column, 100Å, 5 μm, 3.9 
mm × 150 mm with fluorescence detection (450/490 nm ex/em). Based on the known C6 
loading and dosage, data is represented as percent (%) of particles injected.
Histology
Tissue samples from the left lobe of the liver (uninjured), medial lobe (injured) with 
adherent clot, lung, kidney, and spleen were fixed in formalin, soaked overnight in sucrose, 
frozen and cryosectioned to 20-μm thickness. Sections were imaged with an inverted 
fluorescence microscope (Zeiss Axio Observer.Z1). The DsRed filter was used to image 
tissue background fluorescence as a reference channel since staining with VectaShield 
DAPI, or H&E displaced nanoparticles from the tissue.
In vitro Assay
Coagulation assays, using Sprague Dawley rat blood, were performed using the ROTEM’s 
NATEM test in the presence of either saline, GRGDS-NPs, or scrambled GRADSP-NPs as 
previously described.16 The outcomes we considered include the standard ROTEM 
parameters clotting time (CT), clot formation time (CFT), the sum of the two (CT+CFT), 
and maximum clot firmness (MCF). CT is defined as the time from the start of the assay 
until the initial clotting is detected (thickness = 2mm). CFT is defined as the time between 
clot initiation until a clot thickness of 20 mm is detected. MCF is defined as the maximum 
thickness (in mm) that a clot reaches during the duration of the test. The dosing study was 
performed blood samples from 10 rats, starting with the highest concentration of particles 
(20 mg/ml, n=5), and titrating downward (2 mg/ml, n=7; 0.2 mg/ml, n=9; 0.02 mg/ml, n=9) 
until no effect was observed (0.002 mg/ml, n=3). Each sample was run in triplicate on the 
ROTEM, normalized to a saline control, and averaged for each rat.
Statistics
ANOVA with ad-hoc Tukey comparisons was used to analyze blood loss and ROTEM data 
(Minitab). 1-hour survival was analyzed with a binomial logistic regression with chi-squared 
tests between odds-ratios (SAS), and survival curves with a log-rank (Mantel-Cox) test. 
Quantification of histology was analyzed with two sample t-tests with Welch’s correction.
RESULTS
GRGDS conjugation density
Polymer nanoparticle characteristics were the same as previously described (Table 1, Figure 
1)16, except for the higher conjugation efficiency of RGD peptide to the activated PEG 
groups (Figure 2). This was accomplished primarily by performing the peptide conjugation 
before nanosphere formation and reacting in organic phase (anhydrous DMSO) rather than 
aqueous to form what we term the quadblock polymer (PLGA-b-p(lys)-b-PEG-b-GRGDS). 
After nanoparticle formation, peptide loading levels were measured with amino acid 
Shoffstall et al. Page 5













analysis and the arginine to lysine ratio was determined to obtain the percentage of polymer 
chains with the GRGDS peptide. Nanoparticles made from the quadblock polymer had 2 
orders of magnitude more GRGDS than the nanoparticles made from triblock polymer used 
in the hemostatic nanoparticles tested previously (Arg:Lys ratio 4.35*10−3 compared to 
0.428).16 The high-RGD-loaded nanoparticles based on the quadblock polymer are referred 
to as GRGDS-NP100 and Scrambled-NP100, while the previously used triblock 
nanoparticles are referred to as GRGDS-NP1 and Scrambled-NP1.
In vitro test of GRGDS NP100
A dosing study with anticoagulated whole rat blood was performed to titrate the optimal 
dose of the NP100 nanoparticles (Figure 3). Rotational thromboelastometery (ROTEM) was 
used to determine clotting time (CT), clot formation time (CFT), and maximum clot 
firmness (MCF). Each sample consisted of 300 μl of anticoagulated blood, 20 μl of a particle 
dosing solution, and 20 μl of CaCl solution to replace the calcium in the blood and initiation 
coagulation. Previously, using the GRGDS-NP1 particles, we found that a particle dosing 
concentration of 2.5 mg/ml (blood concentration = 147 μg/ml) reduced clotting time in this 
in vitro model. When testing the GRGDS-NP100 particles at this same concentration, we 
observed a trend of increased total clotting time (CT+CFT), and a decrease in MCF, 
demonstrating an anticoagulant-like effect (Figure 3a). A dose response was then performed 
to titrate down to the optimal dose for the GRGDS-NP100 particles (Figure 3a–b). We found 
that the optimal dose was at least 10-fold lower, between 0.02–0.25 mg/ml (blood 
concentration = 1.2–14.7 μg/ml). Further testing 0.25 mg/ml at this concentration yielded a 
reduced total clotting time (CT+CFT, p=0.0346 versus saline), with no adverse impact on 
MCF (Figure 3c–d). There was no significant difference between the scrambled and 
GRGDS groups.
NP100 particles in liver injury model
Previous experiments with the low-peptide conjugated nanoparticles (GRGDS-NP1) at 20 
mg/ml concentration in a 0.5 ml carrier solution (40mg/kg) led to increased 1 hour survival 
(80% compared to 47% saline control) in a model of lethal liver trauma.16 When this 
experiment was repeated with high-peptide conjugated nanoparticles (GRGDS-NP100) at 
the same dose concentration (40 mg/kg) and ½ dose (20 mg/kg), survival time was 
drastically reduced from a mean time of 43 minutes (saline) to 28 minutes and 34 minutes, 
respectively, suggesting an adverse effect on the injury model. The effects of NP100 
particles appeared to be harmful until dosing down to 5 mg/kg, at which, 1 hour survival 
increased to 100% for the pilot study with n=3 animals (Figure 4a). Blood loss was also 
significantly reduced compared to the saline control (p=0.0115, Figure 4b).
We then scaled up the study (n=13) at this new dosage, 5 mg/kg. 1-hour survival was 
increased to 92.3% compared to a scrambled peptide control 45% (OR=14.4, 95% CI=[1.36, 
143], power=0.836) a saline control 47% (OR=13.5, 95% CI=[1.42, 125], power=0.888) and 
the previously reported hemostatic nanoparticles 80% (OR=1.3, n.s., Figure 5a). Blood loss, 
as measured by collecting intra-abdominal blood with pre-weighed gauze, was significantly 
decreased from a mean of 26.0 ml/kg (saline) to 19.25 ml/kg (GRGDS-NP100, p=0.0067, 
Figure 5b).
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Compared to the previous liver injury study16, where 40 mg/kg of GRGDS-NP1 particles 
were injected, the present study only used 5 mg/kg of GRGDS-NP100 particles, 1/8 the 
previous mass. We find that similar proportions of the injected dose are found in the tissues, 
with the majority of particles being cleared through the liver (7.5–10.5%) or becoming 
entrapped in the clot (11%) or lungs (2–46%) as measured using an HPLC fluorescence 
assay for C6 (Figure 6). Less than 1% is found in the kidney and spleen, and the particles are 
rapidly cleared from the blood plasma, with only 2% remaining in circulation at the end of 
the 1-hour experiment.
Since biodistribution within anisotropic organs can have a heterogeneous distribution, a 
histological investigation was conducted, looking at the kidney, capillary beds of the deep 
lung, the uninjured left lobe of the liver, and the adherent clot attached to the injured medial 
lobe of the liver (Figure 7). We found that while the proportion of particles accumulating in 
the clot was similar between the GRGDS and scrambled particles (by HPLC), the GRGDS 
particles appeared in clusters rather than individual satellite particles (by histology), 
suggesting that they may be actively participating in platelet aggregation (Figure 7d). The 
number of particles found within the clot (11% injected dose), while a small mass, 
represents a large number of particles, 9.2×109, or a number equivalent to ~50% of the total 
circulating platelets in a 250 g rat (assuming: nanoparticle density, 1.3 g/cm3; rat blood 
volume, 68.6 ml/kg; normal rat platelet concentration 1.180×109/ml)44, 45
The distribution of particles to the capillary beds of the lung was significantly smaller than 
expected for the GRGDS group (Figure 7b), suggesting that the large quantity of particles 
found in the GRGDS-NP100 group, by the HPLC assay of the whole lung tissue, is not 
collected in the capillary beds, and must be accumulating in higher order branches.
DISCUSSION
Internal hemorrhage is currently treated with a combination of i.v. blood products with or 
without additional administration of soluble clotting factors, such as fibrinogen or 
recombinant factor VIIa.35, 46–48 Unfortunately, resuscitative strategies involving blood 
products have the drawbacks necessitating donor sources and refrigeration.46 They also may 
carry the risk for immune responses and suffer from loss of hemostatic activity during 
storage.46 These issues limit the application in first responder situations, which is 
exceptionally important because early intervention is the best predictor of survival following 
trauma. We developed a synthetic substitute for platelet administration to mitigate these 
complications.
We previously showed that administration of GRGDS-NP1 nanoparticles significantly 
improve survival after lethal liver trauma.16 In this first generation system, the GRGDS 
peptide was crucial for function of these nanoparticles binding with the GIIb/IIIa receptor on 
activated platelets to form mechanically robust platelet plugs. In this work, we have gone 
onto investigate the role that peptide density plays in the efficacy and safety of these 
hemostatic nanoparticles. Here, we have increased the targeting ligand concentration on our 
nanoparticles 100-fold and achieved a 92% survival rate when administering GRGDS-
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NP100 (5 mg/kg) compared to 80% from the previous work. The higher peptide-conjugated 
particles, GRGDS-NP100, led to significantly increased survival and significantly reduced 
blood loss at a concentration 8-fold lower than the dose required for the previous GRGDS-
NP1 formulation. 16 This finding is incredibly important because it suggests that peptide 
concentration is a critical variable, and demonstrates the significant impact on effective 
nanoparticle dosage by modulating targeting ligand concentration.
We also found blood loss was significantly reduced with the GRGDS-NP100 at 5 mg/kg. 
This is a significant finding as it continues to show that intravenous hemostatic nanoparticles 
can augment the clotting process, and that this can produce a large impact on survival. 
Furthermore, by reducing the effective dose, we also found that we can improve safety by 
having very few particles in non-injured tissues such as the lungs. Optimizing the targeting 
ligand is critical for the safety and efficacy of this system.
At higher doses (>5 mg/kg), it is evident that the GRGDS-NP100 particles have an adverse 
effect, substantially reducing mean survival time in the lethal liver trauma. These in vivo 
findings are recapitulated by our in vitro observations, that higher doses of the GRGDS-
NP100 hemostatic nanoparticles actually adversely impact hemostasis. Specifically, we find 
that higher doses appear to inhibit the standard ROTEM parameters of clotting time and, to a 
lesser degree, maximum clot firmness. This sort of response, where a dose that is too high or 
too low is not effective, has been previously reported.15, 17
These observations are likely the result of a saturation effect of the endogenous platelets. 
Too many platelet-bound nanoparticles could theoretically sterically hinder or saturate the 
receptors on the activated platelets leading to reduced platelet-platelet interactions and 
inhibition of their aggregation. These findings suggest that titrating the correct dosing in 
vitro will be crucial as this technology moves forward into large animal and potentially 
clinical trials.
We previously found that accumulation of nanoparticles in the lungs was independent of 
peptide targeting, with ~2 mg dose accumulation in the lung for both the GRGDS-NP1 and 
Scrambled-NP1 particles.16 However, peptide density does appear to have an effect, with a 
higher percentage of injected GRGDS-NP100 accumulating in the lungs than scrambled-
NP100, but at smaller total particle mass with the GRGDS-NP100 (0.57 mg) than the 
GRGDS-NP1 (2 mg) due to the lower effective dose. Lung accumulation was further 
investigated histologically and revealed extremely few, sparsely distributed nanoparticles in 
sections of the deep capillary beds of the lungs. Virtually no particles were found in the 
capillary beds of the deep lung tissue, where potential complications could arise as a result 
of nanoparticle aggregates.49–51 It is possible that if particles are associating with clots, as 
has been previously suspected16, 52, 53, and are subsequently shed from the injury site, these 
may be too large to reach the deep lung and are likely being incorporated in the higher order 
vasculature of the lung. The increased number of GRGDS-NP100 particles found in the lung 
in this study would therefore suggest a stronger clot-targeting effect compared to the 
scrambled-NP100, but has the disadvantage of accumulating in what appears to be clots in 
the lung. It may be possible to ameliorate these effects by changing the route of 
administration to one that directly feeds the injury site. Regardless, the question to answer 
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will be whether or not these particles antagonize pulmonary function (e.g. pulmonary artery 
pressure) or increase risk for pulmonary embolism. It is clear that the uptake of particles in 
the various tissues can be widely heterogeneous, and further investigations are required to 
determine the impact of nanoparticles on pulmonary function and assess the risk for 
pulmonary embolism development.
Optimizing targeting ligand conjugation densities to increase targeting potential of 
nanotherapuetics is critical to efficacy and safety of these systems.7–12 It is clear that more 
in not always better.9, 12, 13 Here, we presented a method to tune the density of targeting 
ligands presented on the surface of the intravenous hemostatic nanoparticles, by producing 
them with blends of the GRGDS-NP100 and the nonfunctionalized pegylated polymer, 
PLGA-PLL-PEG. While we developed our methods independently in our lab, other groups 
have taken similar approaches previously.9, 54 Unsurprisingly, this method is more efficient, 
repeatable, and allows for greater control over peptide conjugation than other potential 
approaches such as tuning the stoichiometry or other reaction conditions of the conjugation 
chemistry.9 Interestingly the scrambled peptide, GRADSP, had a slightly higher conjugation 
efficiency in aqueous phase relative to GRGDS, while the GRADSP peptide had a slightly 
lower conjugation efficiency in organic relative to GRGDS, possibly suggesting an 
interaction of the additional hydrophobic proline residue during this reaction in the different 
phases.
One can imagine that functionalized polymer (PLGA-b-p(lys)-b-PEG-b-GRGDS) can be 
blended with the terminally pegylated polymer (PLGA-b-p(lys)-b-PEG), to accurately tune 
the peptide density. As documented by Gu et al.9 the “optimal” window can be extremely 
narrow, and further research is indicated to fully determine optimal blend and dose 
parameters. We have shown here that ROTEM is a potential assay for elucidating the effects 
of these changes in an in vitro system using whole blood, and that the same dose-
relationship trends are observed in an in vivo model of lethal liver trauma.
CONCLUSION
Here, our challenge was to develop a method for reproducibly controlling nano-scale surface 
ligand conjugation and determine the impact of this change on hemostasis. We found using 
ROTEM the efficacious dose of GRGDS-NP100 was 10-fold lower than with previously 
recorded with GRGDS-NP1, and this result was recapitulated in vivo, after lethal liver 
trauma in the rat, showing efficacy at 8-fold lower concentration. Moving this technology 
toward clinical trials will require validation of the initial dose before proceeding. In vitro 
ROTEM testing with human blood may be one method for ascertaining an initial dosage 
estimate as well as provide a mechanism for optimizing surface ligand concentrations. This 
work demonstrates the potential utility of nanomedicine in addressing hemorrhage after 
lethal trauma. We have demonstrated the impact of, and the methods for, tightly control 
surface ligand density to optimize hemostatic efficacy.
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SCANNING ELECTRON MICROSCOPY. Image of nanoparticles under SEM (Hitachi 
S4500).
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AMINO ACID ANALYSIS. Peptide conjugation efficiency Arg:Lys ratio. Peptide 
conjugation levels are approximately 100-fold higher when the conjugation reaction is 
performed in DMSO instead of aqueous phase. This leads to the nomenclature, NP100 and 
NP1 for the organic and aqueous phase polymers respectively. Error bars denote SEM.
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IN VITRO DOSE RESPONSE GRGDS-NP100. a–b) Total clotting time (CT+CFT) and 
maximum clot firmness (MCF) dose-responses, recapitulated the in vivo response observed: 
high doses adversely impact clotting parameters (increase CT+CFT; decrease MCF). This is 
observed until dosing down to 0.02–0.2 mg/ml. C–D) 0.25 mg/ml was then further tested 
directly against a scrambled-NP100 control (n=6). CT+CFT was reduced compared to saline 
(p=0.0346), with no significant impact on MCF. Dotted lines denote normalization to the 
saline-treated controls values. Error bars denote SEM.
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IN VIVO DOSE RESPONSE GRGDS-NP100. Dose response with GRGDS-NP100 in rat 
liver injury model (n=3 for pilot study). b) Percentage of animals surviving to 1-hour is 
reduced in the 40 mg/kg and 20 mg/kg groups, but increased in the 5 mg/kg dose. b) Blood 
loss is significantly reduced in the 5 mg/kg dose, and not significantly changed with either 
40 mg/kg or 20 mg/kg doses compared to the saline control. Error bars denote SEM.
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LIVER INJURY RESULTS NP100. Rat medial liver injury model at 5 mg/kg dose. a) 1-
hour (endpoint) survival was increased to 92%, compared to a scrambled peptide control, 
45% (OR=14.4, 95% CI=[1.36, 143]), a saline control, 47% (OR=13.5, 95% CI=[1.42, 
125]), and GRGDS-NP1, 80% (OR=1.30, n.s.). Survival curves display increased survival 
with GRGDS-NP100 compared to the scrambled and saline groups, log-rank (Mantel-Cox) 
test, p=0.0362. b) Blood loss was significantly reduced in the GRGDS-NP100 group 
compared to saline (p=0.0067). Error bars denote SEM.
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BIODISTRIBUTION (HPLC ASSAY). An assay for fluorescent C6 was performed using 
HPLC. a) There is a large proportion of nanoparticles in the lungs for the targeted GRGDS 
group (~50%). The liver accumulates 7.5–10.5% of the injected dose (GRGDS, scrambled 
respectively), while ~11% becomes entrapped in the adherent clot found in the abdominal 
cavity post-mortem, regardless of the peptide group. Less than 1% is found in the kidney 
and spleen, and the particles are rapidly cleared from the blood plasma, with only 2% 
remaining in circulation at the end of the 1-hour experiment. b) However, due to 8x lower 
dose with NP100, there are fewer nanoparticles by mass in the lungs compared to the NP1. 
Error bars denote SEM.
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HISTOLOGY AND QUANTIFICATION. Histology was performed on the kidneys, 
uninjured left lobe of the liver, lungs, and injured medial lobe of the liver with adherent clot 
intact. Sections are 20 μm, and were not stained to prevent displacement of the 
nanoparticles. Quantification of the particles is measured in triplicate for n=3 rats per group, 
and represented as pixels/mm2. a) Kidneys show no significant differences between 
treatment groups, b) Uninjured liver (left lobe), contains higher density of particles in the 
scrambled group compared to GRGDS (p=0.0467). c) Lungs show a larger proportion of 
particles accumulating in the GRGDS group compared to scrambled, d) Clot adherent to 
remaining liver. Green = coumarin-6 (C6) loaded hemostatic nanoparticles; Red = Tissue 
background fluorescence (DsRed filter) used as reference channel. While the concentration 
of particles in the adherent clot is equal between groups, the particles in the GRGDS group 
appear as clusters, while the scrambled particles appear evenly dispersed. Error bars denote 
SEM.
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Table 1
NP1 and NP100 Characterization: Size and Zeta Potential
Nanoparticle formulation DLS; no. avg. dia. (nm; mean ± SD) Zeta potential (mV; mean ± SD)
GRGDS-NP1 499.4 ± 95.9 −22.6 ± 2.1
GRGDS-NP100 574.9 ± 196. 5 −16.7 ± 5.5
GRADSP-NP1 535.6 ± 133.8 −24.8 ± 6.2
GRADSP-NP100 611.4 ± 219.2 −14.7 ± 2.5
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